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Mutagenic Metabolites of Benzene Detected
in the Microscreen Assay
by Toby G. Rossman,* Catherine B. Klein,* and
Carroll A. Snyder*
The reactive metobolite responsible for benzene hematotoxicity and carcinogenicity is unknown. It can
be hypothesized that the ultimate carcinogen derived from benzene metabolism might also act as a muta-
gen. This laboratory has recently developed a new assay that can detect mutagens ofall types, using a sin-
gle strain ofbacteria, E. coliWP2s (A), as atarget. Different genetic endpointscanbe monitored in the same
exposed population of bacteria. When a number of known metabolites of benzene were assayed, only
trans,trans-muconic acid gave a strongpositive response. Mutations were induced at two genetic loci (Trp+
revertants and T5 resistance). The mutagenic activity was greatly increased when a rat liver metabolizing
system was added. We speculate that trans,trans-muconic acid is metabolized to a diepoxide, which may be
the ultimate mutagen and possibly the ultimate carcinogen.
Introduction
Human exposure to benzene is associated with leuke-
mias, particularly acute myeloblastic leukemia and its
variants (1). In animal studies, leukemias and Zymbal's
gland tumors are observed in rats and mice after ex-
posure to benzene. Other tumors seen include those of
skin and oral cavity in rats, and lung, preputial gland,
mammary gland, and malignant lymphoma in mice (2).
Benzene-induced chromosomal abnormalities have been
produced in mice, with male mice showing more suscep-
tibility than female mice (6-8). Sister chromatid ex-
changes are also produced by exposure to benzene (7).
Workers exposed to lowlevels ofbenzene (less than 10
ppm) were found to have increased chromosomal abnor-
malities in their peripheral lymphocytes (3-5).
There is substantial evidence showing that, although
benzene itselfcannot reactwith DNA or causemutations,
benzene can be metabolized to genotoxic agents. When
radiolabeledbenzene is administered byinhalation, DNA
adducts are found in the liver(9). Incubation ofbone mar-
row mitochondria with labeledbenzene resulted in seven
guanine adducts and two adenine adducts (10). Benzene
is not mutagenic in the Ames test (11), even with meta-
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bolic activation, suggesting that the rat liver activation
system is unable to metabolize benzene to a mutagenic
compound. However, bone marrow enzymes can appar-
entlymetabolize benzene toproductsthat can form DNA
adducts (10).
Results and Discussion
This laboratory has recently developed a new short-
term in vitro assay to detect mutagens ofall' classes us-
ingonly one strain ofbacteria(12-14). The mainfeatures
ofthis assay are showninFigure 1. Serial dilutiorns ofthe
testcompound areaddedto microtiterwellsthat are then
inoculated with E. coli WP2s (A). This strain carries a
uvrA mutation, which renders the bacteria unable to
carry out excision repair ofbulkyadducts; amutation in
the trpE gene, which makes the strain dependent upon
exogenous tryptophan for growth. After overnight
growth in the presence of the test agent, aliquots are
taken from the subtoxic wells andassayed for a number
ofgenetic end points.
Some ofthe metabolites ofbenzene are shown in Fig-
ure 2. When these and some related compounds were
assayed in the Microscreen, only one compound,
trans,trans-muconic acid(ttMA), wasveryactive. Results
with the T5-resistance marker are shown in Figure 3. It
is clearthatalthough slightmutagenic activity canbe de-
tected with ttMA alone, a great enhancement is seen
when ratliver S9 is added. Resultswiththe direct-acting
agent p-propiolactone (BPL) are shown for comparison.ROSSMAN, KLEIN, AND SNYDER
Test Compounds
High
c
0
0-
co ._-
c
0 c
0
LowI
Serial dilutions of test com
down a row of wells. E. cl
well. Wells are clear. Total
TESTS
Endpoint Measured Prophag
MICROSCREEN
C
cJ 0
OVERNIGHT
INCUBATION
.40
ASSAY
-
0
1 2 3 4 5 6 7 8 9 10 11
0000(0000000(* 000o000ooooo
0*06-00060*06 ooo*.oo000ooo. o*o..oo.o0o.
o.o..o*.o.o.
*e*..o..oe..
npounds are made Clear wells indicate toxicity. Turbid wells indicate
:o1i is added to each growth. Sample from first turbid well (circled) and
volume = 250 gl / well next two wells. Compound 5 may have to be
retested at a higher concentration since no toxic
endpoint was seen. Compound 9 must be tested
at lower concentrations since all wells are clear.
SAMPLE
e Induction TRP+ Reversion Ampicillin Resistance T5 Resistance
Mechanism Induction of Base Pair Substitution Base Pair Substitution Any Type of Forward
SOS System by (Ochre Suppression) or Gene Amplification Mutation
DNA Damage
FIGURE 1. Microscreen assay.
BPL appears about 10-fold more active than ttMA + S9.
However, since the molecular weight of ttMA is twice
that of BPL, on a molar basis BPL is about five times
more active than metabolized ttMA.
Table 1 summarizes the results from the three muta-
genesis end points in the Microscreen. The slight activ-
ity with ttMA alone is detected at the same genetic loci
as the much greater activity seen in the presence ofrat
liver S9, suggesting that the E. coli might be able to
metabolize ttMA to the same product(s) to a lesser ex-
tent. The ability to cause Trp + reversion indicates that
abase pair substitution mutagen is formed. Acrylic acid,
which contains a single a, P unsaturated acid moiety, is
not active. It is of interest that benzene itself caused a
slightincrease in ampicillin-resistant mutants. This activ-
ity was notenhanced by ratliver S9 (Table 1). Since this
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FIGURE 2. Some of the benzene metabolites tested for mutagenicity.
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FIGURE 3. Mutagenicity (to T5 resistance) oftrans,trans-muconic acid
(ttMA) with and without metabolic activationby Aroclor-induced rat
liver S9. Results with P-propiolactone (BPL) are included for compar-
ison.
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Tlble 1. Ibxicity and mutagenicity of benzene metabolites and related compounds.
S9 Toxicit Mutagenicity
Compound activation jAg/mI Tr + Amp' T5Y
Benzene 50 - +
+ 50 - +
Hydroquinone 62 - -
+ 500 - - _
Catechol 500 - -
+ 500 - - -
Resorcinol 2500 - -
+ 2500 - - -
trans,trans-Muconic acid - (NT 11O)a + - +
+ (NT 110)a ++++ - ++++
Acrylic acid 96 - NDb
+ 96 - ND
aNot toxic at 110 pg/mL. Higher concentrations were insoluble.
bND, not determined.
marker can detect gene amplification (15), it is possible
that benzene itself can induce gene amplification by a
mechanism that does not involve DNA adducts.
We speculate that the ultimate mutagenic agent(s) de-
rived from benzene is one or more diepoxides formed
from ttMA. These compounds would be analogues of
diepoxybutane, but with two carboxylgroups. Diepoxy-
butane is a known animal carcinogen (16).
Our data suggest that the liveris unable toform ttMA
from benzene, but ifttMA is formed elsewhere, liver en-
zymes are able to metabolize it further to mutagenic
metabolites. Itispossible thatbonemarrow enzymes are
able to produce ttMA and its metabolites from benzene.
Ifso, this would explain the organ specificity ofbenzene
toxicity and carcinogenicity.
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